Fluctuation of lacosamide serum concentrations during the day and occurrence of adverse drug reactions - First clinical experience

Epilepsy Research

Volumn 95, Issue 3, 2011, Pages 207-212

  Sattler, Annika ^a,c   Schaefer, Marion ^c   May, Theodor W ^b   Rambeck, Bernhard ^b   Brandt, Christian ^a,b  

^a EPILEPSY CENTER BETHEL   (Germany)

^b Biochemisches Labor der Gesellschaft für Epilepsieforschung   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adverse drug reactions; Antiepileptic drugs; Epilepsy; Lacosamide; Therapeutic drug monitoring

Indexed keywords

BROMOCRIPTINE; CARBAMAZEPINE; ETIRACETAM; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PRIMIDONE; VALPROIC ACID; ZONISAMIDE;

ADD ON THERAPY; ADULT; ARTICLE; ATAXIA; BODY EQUILIBRIUM; CLINICAL ARTICLE; CONTROLLED STUDY; DIPLOPIA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; FEMALE; FOCAL EPILEPSY; HEADACHE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; NYSTAGMUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR; VOMITING;

ACETAMIDES; ADULT; ANTICONVULSANTS; CHROMATOGRAPHY, LIQUID; DRUG TOXICITY; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 79960353827     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2011.03.019     Document Type: Article

References (13)

1. Ben-Menachem E., Biton V., Jatuzis D., Abou-Khalil B., Doty P., Rudd D. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007, 48:1308-1317.
2. Brandt C., Baumann G., Eckermann G., Hiemke C., May T.W., Rambeck B., Pohlmann-Eden B. Therapeutic drug monitoring in Epileptologie und Psychiatrie. Nervenarzt 2008, 79:167-174.
3. Cawello W., Nickel B., Eggert-Formella A. No Pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J. Clin. Pharmacol. 2010, 50:459-471.
4. European Medicines Agency, 2008a. European Public Assessment Report (EPAR) Vimpat. Available from: (accessed 05.07.10). http://www.ema.europa.eu/humandocs/PDFs/EPAR/vimpat/H-863-en1.pdf.
5. European Medicines Agency, 2008b. Summary of product characteristics: Vimpat. Available from: (accessed 05.07.10). http://www.ema.europa.eu/humandocs/PDFs/EPAR/vimpat/emeacombined-h863en.pdf.
6. Halász P., Kälviäinen R., Mazurkiewicz-Beldzińska M., Rosenow F., Doty P., Hebert D., Sullivan T. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009, 50:443-453.
7. Halford J.J., Lapointe M. Clinical perspectives on lacosamide. Epilepsy Curr. 2009, 9:1-9.
8. Heinzel G., Woloszak R., Thomann P. TOPFIT 2.0. Pharmacokinetics and Pharmacodynamic Data Analysis System for the PC 1993, Gustav Fischer, Stuttgart.
9. Horstmann R., Bonn R., Cawello W., Doty P., Rudd D. Basic clinical pharmacologic investigations of the new antiepileptic drug SPM 927. Epilepsia 2002, 43:188.
10. May T.W., Brandt C., Kassel J. Evaluation of a self-report questionnaire for the assessment of adverse effects of antiepileptic drugs. Epilepsia 2009, 50:104.
11. Noachtar S., von Maydell B., Fuhry L., Büttner U. Gabapentin and carbamazepine affect eye movements and posture control differently: a placebo-controlled investigation of acute CNS side effects in healthy volunteers. Epilepsy Res. 1998, 31:47-57.
12. Specht U., May T.W., Rohde M., Wagner V., Schmidt R.C., Schutz M., Wolf P. Cerebellar atrophy decreases the threshold of carbamazepine toxicity in patients with chronic focal epilepsy. Arch. Neurol. 1997, 54:427-431.
13. Thomas D., Doty P., Horstmann R., Scharfenecker U., Nickel B., Yates S. Lacosamide has low potential for drug-drug interaction (Poster). Presented at the 61st Annual American Epilepsy Society Meeting 2007.